Topic: Rodent Study

1 chapters across the catalog

The FDA's approval of the new bivalent COVID-19 booster is criticized for being based on a study involving only eight mice rather than comprehensive human trials. Dr. Alexander notes that Pfizer's original data showed a much lower absolute risk reduction than the 95% relative risk reduction advertised. He concludes that the relationship between pharmaceutical companies and federal regulatory agencies has become collusive and fraudulent.